Navidea Biopharmaceuticals (NAVB)
Add to Watchlists Create an AlertNAVB Key Stats
| Income Statement | |
| Revenue TTM | 0.0787M |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -0.2885 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -29.16M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -106283% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 286.97M |
| Enterprise Value | 287.54M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | |
| Free Cash Flow | -7.367M |
| Return on Equity | -309.4% |
NAVB News
- Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joi... May 22
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Defin... May 16
- Angelina Jolie's Selfless Act Heightens Breast Cancer Awareness May 15
- Nordion signs contract manufacturing agreement with Navidea May 15
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with Nordion Business Wire May 15
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 10
- NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and F... May 9
- Navidea Biopharmaceuticals, Inc Management Discusses Q1 2013 Results - Earnings ... May 8
- Navidea Biopharma (NAVB) Posts Narrower than Expected Q1 Loss Street Insider May 8
- Q1 2013 Navidea Biopharmaceuticals Inc Earnings Release - Before Market Open May 8
NAVB Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Navidea Biopharmaceuticals is down 11.27% over the last year vs S&P 500 Total Return up 27.77%, Abiomed up 0.27%, and Guided Therapeutics up 1.18%.
NAVB Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these NAVB related companies
Pro Ratings for NAVB
Pro Report PDF for NAVB
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download NAVB Pro Report PDF
Pro Strategies Featuring NAVB
Did Navidea Biopharmaceuticals make it into our Pro Portfolio Strategies?
NAVB Profile
Sector: Healthcare
Industry: Medical Devices
Other NAVB Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NAVB | 2.44 | -0.06 | -2.40% | 286.97M |
